Company Performance Metrics
Hiroshi Muto: Chief Operating Officer, SFJ Pharma Japan K.K.
Rolf Linke: Independent Consultant for Medical Affairs and Clinical Development
The SFJ Pharmaceuticals Group ® mission is to accelerate the availability of new and innovative drugs into the world’s major markets, by providing not only additional funding, but also strategic development expertise to enable our Pharma and Biotech partners to be as hands off or as hands on as they wish.
Currently there is significant downward
pressure on drug development resources. In the case of large Pharma the so called “patent cliff” has hit hard leaving no company unaffected. This leads to dramatic R+D budget cuts. For Biotech there is a chronic lack of external funding available.
The SFJ Pharmaceuticals Group ® mission is to enable these companies to continue to develop their most important drug candidates without increasing the burden on their P&L or cash reserves. SFJ will take 100% of the clinical and regulatory risk.
